- Stocks
- Healthcare
- NASDAQ: VRTX

Price (delayed)

$183.49

Market cap

$47.6B

P/E Ratio

23.89

Dividend/share

N/A

EPS

$7.68

Enterprise value

$42.43B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather

The price to earnings (P/E) is 66% less than the 5-year quarterly average of 70.6

The gross profit has grown by 24% YoY and by 4% from the previous quarter

VRTX's debt has soared by 71% YoY

The EPS has declined by 28% since the previous quarter and by 4.2% year-on-year

What are the main financial stats of VRTX

Market
Valuations
Earnings

Shares outstanding

259.43M

Market cap

$47.6B

Enterprise value

$42.43B

Price to earnings (P/E)

23.89

Price to book (P/B)

5.16

Price to sales (P/S)

7.11

EV/EBIT

17.16

EV/EBITDA

16.39

EV/Sales

6.35

Revenue

$6.68B

EBIT

$2.47B

EBITDA

$2.59B

Free cash flow

$1.78B

Per share
Balance sheet
Liquidity

EPS

$7.68

Free cash flow per share

$6.86

Book value per share

$35.53

Revenue per share

$25.81

TBVPS

$41.78

Total assets

$12.22B

Total liabilities

$3.03B

Debt

$893.85M

Equity

$9.2B

Working capital

$6.62B

Debt to equity

0.1

Current ratio

4.61

Quick ratio

4.16

Net debt/EBITDA

-2

Margins
Efficiency
Dividend

EBITDA margin

38.7%

Gross margin

87.9%

Net margin

29.8%

Operating margin

33.9%

Return on assets

16.8%

Return on equity

22.8%

Return on invested capital

72.5%

Return on capital employed

23.8%

Return on sales

37%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Vertex Pharmaceuticals stock price performed over time

Intraday

-0.07%

1 week

-1.17%

1 month

-8.22%

1 year

-31.58%

YTD

-22.36%

QTD

-9%

How have Vertex Pharmaceuticals's revenue and profit performed over time

Revenue

$6.68B

Gross profit

$5.87B

Operating income

$2.27B

Net income

$1.99B

Gross margin

87.9%

Net margin

29.8%

VRTX's net margin is down by 31% QoQ and by 23% YoY

The operating margin has decreased by 28% QoQ and by 13% YoY

Vertex Pharmaceuticals's net income has decreased by 28% QoQ and by 4.3% YoY

The operating income has declined by 25% since the previous quarter but it has grown by 8% year-on-year

What is Vertex Pharmaceuticals's growth rate over time

What is Vertex Pharmaceuticals stock price valuation

P/E

23.89

P/B

5.16

P/S

7.11

EV/EBIT

17.16

EV/EBITDA

16.39

EV/Sales

6.35

The price to earnings (P/E) is 66% less than the 5-year quarterly average of 70.6

The EPS has declined by 28% since the previous quarter and by 4.2% year-on-year

The stock's price to book (P/B) is 60% less than its 5-year quarterly average of 12.9 and 25% less than its last 4 quarters average of 6.9

The equity has grown by 22% YoY and by 2.4% from the previous quarter

The price to sales (P/S) is 47% less than the 5-year quarterly average of 13.3 and 26% less than the last 4 quarters average of 9.6

VRTX's revenue is up by 24% YoY and by 4.2% QoQ

How efficient is Vertex Pharmaceuticals business performance

The return on invested capital has declined by 32% since the previous quarter and by 8% year-on-year

VRTX's return on assets is down by 31% since the previous quarter and by 29% year-on-year

The return on equity has declined by 31% since the previous quarter and by 31% year-on-year

The return on sales has declined by 29% since the previous quarter and by 13% year-on-year

What is VRTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for VRTX.

How did Vertex Pharmaceuticals financials performed over time

Vertex Pharmaceuticals's current ratio has increased by 24% YoY and by 5% from the previous quarter

Vertex Pharmaceuticals's total assets has increased by 20% YoY

VRTX's debt is 90% lower than its equity

VRTX's debt has soared by 71% YoY

The debt to equity rose by 43% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.